Program
HPP737
A development code. Also written as “HPP737 20mg”.
Its studies are mostly in Psoriasis, led by Newsoara Biopharma.
Furthest: phase 3, since Jul 7, 20264 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newsoara Biopharma | 41 open or running | phase 3since Jul 7, 2026 | Aug 5, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 5, 2024First study: no phase study in PsoriasisFirst studyNCT06584058 · 8 planned · China
- Jul 6, 2026Phase 2 study in PsoriasisNCT07707141 · 123 enrolled · China
- Jul 7, 20262 phase 3 studies in PsoriasisPhase 3 reachedNCT07712731, NCT07712705
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07712731Psoriasis · China | 3 | Completed | Apr 1, 2026 | 607 |
| NCT07712705Psoriasis · China | 3 | Completed | Sep 29, 2023 | 515 |
| NCT07707141Psoriasis · China | 2 | Completed | Dec 20, 2021 | 123 |
| NCT06584058Psoriasis · China | – | Not yet recruiting | Jul 30, 2025 | 8 |
How it is read
Names in the registry
- “HPP737”, 3 entries
- “HPP737 20mg”, 1 entry
Codes read as this program: HPP737.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.